Compugen Stock

Compugen EBITDA Margin

Delisted·Jun 15, 2026

The EBITDA Margin of Compugen (CGEN) as of Aug 3, 2026 is 43.05 %. In the previous year, EBITDA Margin was -53.44 % — a change of -180.56% (higher).

EBITDA Margin

43.05 %

YoY

-180.56%

Last updated:

EBITDA Margin of Compugen is 2026 43.05 % . EBITDA Margin of Compugen was 2025 -53.44 % . It decreases by -180.56% higher compared to the previous year.
Access this data via the Eulerpool API

Compugen Stock analysis

What does Compugen do? Compugen Ltd is an Israeli biotechnology company focused on the development of therapeutics and diagnostic products. It was founded in 1993 and is headquartered in Tel Aviv. Compugen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compugen stock

EBITDA Margin of Compugen is 43.05 % in 2026.

EBITDA Margin of Compugen changed from -53.44 % to 43.05 %, representing a -180.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Compugen since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Compugen with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

Margins — Compugen

All Key Metrics — Compugen